SCHEMBL2608495

SCHEMBL2608495

COC(=O)Sc1ccccn1

nearest known ligand 0.47

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.47
SMN1; SMN2 Q16637 6/20 0.47
RAB9A P51151 5/20 0.47
HPGD P15428 5/20 0.47
EHMT2 Q96KQ7 1/20 0.47
EHMT1 Q9H9B1 1/20 0.47
APOBEC3G Q9HC16 1/20 0.47
ALDH1A1 P00352 6/20 0.46
MAPK10 P53779 1/20 0.46
RGS12 O14924 1/20 0.46
MAPT P10636 1/20 0.46
HSD17B10 Q99714 2/20 0.45
PKM P14618 2/20 0.45
MEN1 O00255 1/20 0.45
KMT2A Q03164 1/20 0.45
NPC1 O15118 3/20 0.45
TP53 P04637 1/20 0.45
KDM4E B2RXH2 1/20 0.43
ALOX15 P16050 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4351146 0.81 LMNA (0.44) LMNASMN1; SMN2RAB9AHPGDEHMT2
SCHEMBL1343544 0.79 EHMT2 (0.44) LMNASMN1; SMN2RAB9AHPGDEHMT2
SCHEMBL4757038 0.79 EHMT2 (0.52) LMNASMN1; SMN2RAB9AHPGDEHMT2
SCHEMBL3075428 0.78 EHMT2 (0.56) LMNASMN1; SMN2RAB9AHPGDEHMT2
SCHEMBL5633792 0.78 EHMT2 (0.56) LMNASMN1; SMN2RAB9AHPGDEHMT2
SCHEMBL13979666 0.77 LMNA (0.48) LMNASMN1; SMN2RAB9AHPGDEHMT2
SCHEMBL6420708 0.77 MAPT (0.59) LMNASMN1; SMN2RAB9AHPGDALDH1A1
SCHEMBL1479297 0.76 ALDH1A1 (0.55) LMNASMN1; SMN2RAB9AHPGDEHMT2
SCHEMBL3441413 0.76 ALDH1A1 (0.52) LMNASMN1; SMN2HPGDALDH1A1MAPT
SCHEMBL12109353 0.75 ALDH1A1 (0.46) LMNASMN1; SMN2RAB9AHPGDEHMT2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8377647-B2 Nonseparation assay methods BECKMAN COULTER, INC. (US) 2013-02-19 US disclosed
US-20120094313-A1 Nonseparation Assay Methods BECKMAN COULTER, INC. (US) 2012-04-19 US disclosed
US-20110269156-A1 Nonseparation Assay Methods BECKMAN COULTER, INC. (US) 2011-11-03 US disclosed
US-7923214-B2 Nonseparation assay methods BECKMAN COULTER, INC. (US) 2011-04-12 US disclosed
US-20110009293-A1 Nonseparation Assay Methods BECKMAN COULTER, INC. (US) 2011-01-13 US disclosed
US-7799534-B2 Nonseparation assay methods BECKMAN COULTER, INC. (US) 2010-09-21 US disclosed
US-20070264665-A1 Nonseparation assay methods BECKMAN COULTER, INC. 2007-11-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110009293-A1 Nonseparation Assay Methods FCER2, NTRK1, FCGR2A LMNA 966/4885SMN1; SMN2 4234/4885RAB9A 4757/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.